Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
35,563,928
-
Shares change
-
-9,010,846
-
Total reported value, excl. options
-
$34,226,317
-
Value change
-
-$9,550,880
-
Number of buys
-
26
-
Number of sells
-
57
-
Price
-
$0.9626
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q2 2022
As of 30 Jun 2022 Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) had 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 35,563,928 shares of stock of the company.
Largest 10 holders included Bain Capital Life Sciences Investors, LLC, Artal Group S.A., Ally Bridge Group (NY) LLC, Flagship Pioneering Inc., VANGUARD GROUP INC, FMR LLC, Omega Fund Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Samsara BioCapital, LLC, and BlackRock Inc..
This table shows 58 institutional shareholders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.